Abstract Number: 397 • 2019 ACR/ARP Annual Meeting
Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases characterized by proximal myositis. Dysphagia has been reported to develop in 35 to 62% of…Abstract Number: 398 • 2019 ACR/ARP Annual Meeting
Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong
Background/Purpose: Seasonal patterns of disease onset and severity in idiopathic inflammatory myopathies (IIMs) as a whole are conflicting. In recent years, over 10 myositis-specific antibodies…Abstract Number: 407 • 2019 ACR/ARP Annual Meeting
Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases affecting multiple organ systems and associated with a diverse autoantibody profile. Anti-SSA/SSB are the most frequent…Abstract Number: 1275 • 2019 ACR/ARP Annual Meeting
Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases with systemic features and multiple comorbidities. Of the myositis associated antibodies seen in this population, anti-SSA/SSB…Abstract Number: 1293 • 2019 ACR/ARP Annual Meeting
Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare chronicinflammatory disorders with significant associated morbidityand mortality despite treatment, characterized by subacute onset of proximal muscle weakness,…Abstract Number: 1870 • 2019 ACR/ARP Annual Meeting
NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis
Background/Purpose: Differentiating smouldering disease activity from weakness due to fatty replacement of atrophied muscle can often be a challenge in Idiopathic Inflammatory Myositis (IIM). There…Abstract Number: 1210 • 2018 ACR/ARHP Annual Meeting
Sonographic Appearance of Inflammatory Myopathies: Increased Muscle Echointensity and Qualitative Changes
Background/Purpose: The use of ultrasound in the assessment of muscle conditions has grown over the years. Various myopathies have shown an increase in echo intensity…Abstract Number: 277 • 2016 ACR/ARHP Annual Meeting
Abnormal Composition of Circulating T and B Cells in Patients with Polymyositis and Dermatomyositis Is More Biased in Those with Interstitial Lung Diseases
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic inflammatory myopathies. They sometimes accompany interstitial lung disease (ILD), which can lead often to fatal outcome. For…Abstract Number: 948 • 2015 ACR/ARHP Annual Meeting
Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response
Background/Purpose: There is a variable response rate to Intravenous immunoglobulin (IVIG) in patients with autoimmune myopathies. The aim of this study was to determine whether…Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…Abstract Number: 2222 • 2014 ACR/ARHP Annual Meeting
Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry
Background/Purpose: Little is known about medications received for myositis and patients’ responses to therapies. We present information on self-reported myositis therapy use and responses from…Abstract Number: 1261 • 2014 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Pulmonary arterial hypertension…Abstract Number: 221 • 2012 ACR/ARHP Annual Meeting
Expanding the Clinical and Serological Spectrum of MDA5-Associated Dermatomyositis
Background/Purpose: Dermatomyositis (DM) is a heterogeneous systemic disease with specific autoantibodies (Abs) which correlate with unique clinical phenotypes. Melanoma differentiation-associated gene 5 (MDA5) Abs have…